Ocular Therapeutix™ to Provide Corporate Update During 43rd Annual J.P. Morgan Healthcare Conference Presentation

Rhea-AI Summary

Ocular Therapeutix (NASDAQ: OCUL) announced its upcoming presentation at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025, at 5:15 PM PT in San Francisco. Pravin U. Dugel, MD, the company's Executive Chairman, President and CEO, will provide updates on several key areas including:

- The enrollment status of SOL-R, their second registrational trial of AXPAXLI™ for treating wet age-related macular degeneration (wet AMD)
- Future opportunities for AXPAXLI
- A general corporate overview and strategic outlook for 2025

The presentation will be accessible through the Events and Presentations section of the company's Investor Relations webpage.

Company presentation scheduled on Monday, January 13th at 5:15 PM PT

Ocular to provide enrollment update for SOL-R, Ocular’s second registrational trial of AXPAXLI™ in wet AMD, future opportunities for AXPAXLI, and a general corporate overview

BEDFORD, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) --  Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today announced that the Company will present its strategic outlook for 2025 at the 43^rd Annual J.P. Morgan Healthcare Conference on January 13, 2025 at 5:15 PM PT in San Francisco, CA.

Pravin U. Dugel, MD, Ocular’s Executive Chairman, President and CEO, will provide an update regarding the enrollment status of SOL-R, the Company’s second registrational trial of AXPAXLI™ for the treatment of wet age-related macular degeneration (wet AMD), future opportunities for AXPAXLI, and a general corporate overview.

43^rd Annual J.P. Morgan Healthcare Conference Presentation Details
Presentation Date: Monday, January 13, 2025
Presentation Time: 5:15 PM PT
Presenter: Pravin U. Dugel, MD, Executive Chairman, President and CEO
Location: San Francisco, CA

The live presentation can also be accessed by visiting the Ocular Therapeutix website on the Events and Presentations section of the Investor Relations page.

About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions. AXPAXLI™ (axitinib intravitreal injection, also known as OTX-TKI), Ocular’s product candidate for retinal disease, is based on its ELUTYX™ proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD).

Ocular’s pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA®, an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery and ocular itching associated with allergic conjunctivitis, and in its product candidate PAXTRAVA™ (travoprost intracameral injection or OTX-TIC), which is currently in a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension.

Follow the Company on its website, LinkedIn, or X.

The Ocular Therapeutix logo and DEXTENZA® are registered trademarks of Ocular Therapeutix, Inc. AXPAXLI™, PAXTRAVA™, ELUTYX™, and Ocular Therapeutix™ are trademarks of Ocular Therapeutix, Inc.

Investors & Media
Ocular Therapeutix, Inc.
Bill Slattery
Vice President, Investor Relations
bslattery@ocutx.com

FAQ

When is Ocular Therapeutix (OCUL) presenting at the J.P. Morgan Healthcare Conference 2025?

Ocular Therapeutix is scheduled to present on Monday, January 13, 2025, at 5:15 PM PT in San Francisco, CA.

What will be discussed in OCUL's J.P. Morgan Healthcare Conference presentation?

The presentation will cover the enrollment status of SOL-R trial for AXPAXLI in wet AMD, future opportunities for AXPAXLI, and a general corporate overview for 2025.

What is the current status of OCUL's SOL-R trial for AXPAXLI?

The enrollment status update for the SOL-R trial, which is OCUL's second registrational trial of AXPAXLI for wet AMD treatment, will be provided during the conference presentation on January 13, 2025.

How can investors access OCUL's J.P. Morgan Healthcare Conference presentation?

Investors can access the live presentation through the Events and Presentations section of the Investor Relations page on Ocular Therapeutix's website.